Sky Zoster, the world's second and the nation’s first vaccine developed by SK Bioscience, has surpassed 1 million doses in accumulated sales.
SK Bioscience said on March 12 that its self-developed shingles vaccine "Sky Zoster" surpassed the 1 million doses in domestic sales as of December last year. This is the result of two years since the launch of the product.
The tally of IQVIA, a drug market research firm, showed that Sky Zoster's market share in terms of sales stood at 47.4 percent in the fourth quarter of last year, which is more than half of the total. SK Bioscience expects to achieve 100 billion won in accumulated sales soon.
Considering the nature of the drug, which is prescribed in earnest after examining market reactions after its release, Sky Zoster's debut as a blockbuster product in two years is considered an unusual achievement.
SK Bioscience believes that it has been effective in targeting the market based on such advantages as superior clinical data, cutting-edge production facilities, high-tech production facilities, diversified sales outlets through co-promotion, and reasonable prices.
SK Bioscience is planning to expand its market share by supplying Sky Zoster, which has settled in the market at a fast pace, in a stable manner and to target global markets starting with emerging markets such as Southeast Asia this year.
"As the aging population is going on, the sales of Sky Zoster will continue to increase due to the increasing people’s interest in shingles vaccine," said Ahn Jae-yong, CEO of SK Bioscience.